Thermo Fisher Scientific (TMO) Current Deferred Revenue (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Current Deferred Revenue for 18 consecutive years, with $2.9 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Deferred Revenue rose 4.03% year-over-year to $2.9 billion; the trailing twelve-month figure through Jun 2026 stood at $2.9 billion (up 4.03% YoY), and the FY2025 full-year result was $2.7 billion, down 4.98% from the prior year.
• Current Deferred Revenue held at $2.9 billion in Q2 2026 per TMO's latest filing, from $2.9 billion in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $2.9 billion in Q1 2026 and bottomed at $2.5 billion in Q3 2023.
• Historically, Current Deferred Revenue has averaged $2.7 billion across 5 years, with a median of $2.7 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue jumped 105.66% in 2022, then dropped 7.28% in 2023.
• Over 5 years, Current Deferred Revenue stood at $2.6 billion in 2022, then rose by 3.38% to $2.7 billion in 2023, then climbed by 6.06% to $2.9 billion in 2024, then retreated by 4.98% to $2.7 billion in 2025, then grew by 7.68% to $2.9 billion in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $2.9 billion, $2.9 billion, and $2.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.